Drugs Xagena
The NICE ( National Institute for Health and Clinical Excellence ) has published final guidance on the use of Rituximab ( Mabthera; US: Rituxan ) for the treatment of rheumatoid arthritis and Adalimum ...
Bayer Schering Pharma AG and Genzyme Europe BV have informed Healthcare Professionals on six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic ...
Rituximab ( MabThera; US: Rituxan ) is a monoclonal antibody representing a glycosylated immunoglobulin indicated for the treatment of: - Non-Hodgkins lymphoma: in combination with chemotherapy fo ...
Rituximab ( MabThera; US: Rituxan ) is a monoclonal antibody representing a glycosylated immunoglobulin indicated for the treatment of: - Non-Hodgkins lymphoma: in combination with ...
Roche has announced new Phase II efficacy data from the investigational compound GA101 ( RG 1759; Obinutuzumab ) in relapsed / refractory non-Hodgkin's lymphoma ( NHL ).GA101 is the first type II ...
The European Commission has granted marketing authorization for Zydelig ( Idelalisib ), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers, chronic lymphocytic leukemia ( ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
The Committee for Medicinal Products for Human Use ( CHMP ) of European Medicine Agency ( EMA ) has adopted a positive opinion for Gazyvaro ( Obinutuzumab; Gazyva in U.S. ) in combination with Bendam ...
The European Commission has granted conditional marketing authorisation for Polivy ( Polatuzumab vedotin ), in combination with Bendamustine plus MabThera ( Rituximab ) ( BR ), for the treatment of ad ...
